Quizartinib Dihydrochloride

5 trials 3 recruiting Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

2 Completed trials

3 Sponsors

22 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 1 Phase I/II: 2

Oversight events:

3 serious breaches across 2 trials

View oversight register →

Indications tested

Acute myeloid leukaemia 1 Fms-like tyrosine kinase 3 positive 1

Sponsors using this IMP

Daiichi Sankyo Inc. 2 Fundacion PETHEMA 2 Prinses Maxima Centrum voor Kinderoncologie B.V. 1

All trials

5 total

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Phase III 15 countries Daiichi Sankyo Inc.
CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit… Recruiting

2023-505000-27-01 Phase II 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting

2025-522979-29-00 Phase III 1 country Fundacion PETHEMA
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood Ended

2023-510009-16-00 Phase I/II 7 countries Daiichi Sankyo Inc.
A multicentre clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax… Ended

2024-519275-26-00 Phase I/II 1 country Fundacion PETHEMA

Showing 1–5 of 5 trials

← All drugs A–Z